Structure-based design of covalent Siah inhibitors

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• The E3 ubiquitin ligase Siah (Seven in absentia homolog 1) plays a crucial role in cellular processes implicated in cancer development and progression.
• Inhibiting Siah is a promising therapeutic strategy, with disruption of its protein-protein interactions being a key focus.
• Traditional drug discovery methods have faced challenges in identifying effective inhibitors for Siah-target interactions.

Purpose of the Study:

• To develop a novel strategy for identifying inhibitors of the E3 ubiquitin ligase Siah.
• To design and validate peptide mimetics that covalently inhibit Siah function.
• To assess the efficacy of these inhibitors in antagonizing Siah-dependent signaling pathways.

Main Methods:

• Utilized a rational structure-based drug design approach.
• Employed peptide mimetics engineered for specific covalent bond formation with Siah.
• Validated inhibitor efficacy using X-ray crystallography, mass spectrometry, and functional cellular assays.

Main Results:

• Successfully identified potent covalent inhibitors of Siah using the structure-based design strategy.
• Demonstrated that these peptide mimetics effectively antagonize Siah-dependent regulation of Erk and Hif signaling pathways.
• Confirmed inhibitor binding and mechanism of action through structural and biochemical analyses.

Conclusions:

• A rational structure-based design strategy enabled the discovery of effective covalent Siah inhibitors.
• Peptide mimetics targeting Siah can successfully inhibit cancer-relevant signaling pathways.
• This approach offers a potentially generalizable strategy for designing peptide-based inhibitors against other protein-protein interactions.